Investing.com - Emergent Biosolutions (NYSE: EBS) reported fourth quarter EPS of $-0.31, $0.35 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $331M versus the consensus estimate of $297.18M.
Guidance
Emergent Biosolutions sees FY 2023 revenue of $1.15B versus the analyst consensus of $1.18B.
Emergent Biosolutions's stock price closed at $14.00. It is up 13.82% in the last 3 months and down -66.17% in the last 12 months.
Emergent Biosolutions saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Emergent Biosolutions's stock price’s past reactions to earnings here.
According to InvestingPro, Emergent Biosolutions's Financial Health score is "great performance".
Check out Emergent Biosolutions's recent earnings performance, and Emergent Biosolutions's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar